Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Manipulation

<< Previous

Bullboard Posts

Next >>

Comment by Antonius2on Nov 12, 2021 5:24pm

94 Views

Post# 34121812

RE:RE:RE:Manipulation

Once good news is released and verified it is unlikely that the price manipulation will continue. Without any competing drugs in the AKI space it is likely that Arch Biopartners will be courting offers from major pharmaceutical companies that would love to be the sole providers of a drug with this market potential. I think that, with the large insider and F&F holdings, we shareholders are aligned with management and will get a fair - if not excellent valuation for Arch.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading